ArticleCancers2022

Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry.

Maximilian Haist et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.